Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America
Open Access
- 6 July 2021
- journal article
- research article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 20 (1) , 67-77
Abstract
Background There are concerns that high prices of cancer medicines may limit patient access. Since information on prices for cancer medicines and their impact on affordability is lacking for several countries, particularly for lower income countries, this study surveys prices of originator cancer medicines in Europe and Latin America and assesses their affordability. Methods For 19 cancer medicines, public procurement and ex-factory prices, as of 2017, were surveyed in five Latin American (LATAM) countries (Brazil, Chile, Colombia, Mexico, and Peru) and 11 European countries (Austria, France, Germany, Greece, Hungary, the Netherlands, Poland, Romania, Spain, Sweden, and the UK). Price data (public procurement prices in LATAM and ex-factory prices in Europe) in US dollar purchasing power parities (PPP) were analyzed per defined daily dose. Affordability was measured by setting medicines prices in relation to national minimum wages. Results The prices of cancer medicines varied considerably between countries. In European countries with higher levels of income, PPP-adjusted prices tended to be lower than in European countries of lower income and LATAM countries. Except for one medicine, all surveyed medicines were considered unaffordable in most countries. In European countries of lower income and LATAM countries, more than 15 days’ worth of minimum wages would be required by a worker to purchase one defined daily dose of several of the studied medicines. Conclusions The high prices and large unaffordability of cancer medicines call for strengthening pricing policies with the aim of ensuring affordable treatment in cancer care.Keywords
This publication has 74 references indexed in Scilit:
- Mapping the availability, price, and affordability of antiepileptic drugs in 46 countriesEpilepsia, 2012
- Delivering affordable cancer care in high-income countriesThe Lancet Oncology, 2011
- High medicine prices and poor affordabilityCurrent Opinion in Psychiatry, 2011
- Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countriesBulletin of the World Health Organization, 2011
- Expansion of cancer care and control in countries of low and middle income: a call to actionThe Lancet, 2010
- Fundo Estratégico da Organização Pan-Americana da Saúde: mecanismo facilitador para melhorar o acesso aos medicamentosRevista Panamericana de Salud Pública, 2010
- International price comparisons of Alzheimer's drugs: a way to close the affordability gapInternational Psychogeriatrics, 2009
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion QuestionJNCI: Journal of the National Cancer Institute, 2009
- International Prices And Availability Of Pharmaceuticals In 2005Health Affairs, 2008
- Cost of Cancer Care: Issues and ImplicationsJournal of Clinical Oncology, 2007